TYAN Introduces HPC, Cloud and Storage Server Platforms Featuring 4th Gen AMD EPYC™ Processors at SC22
15.11.2022 18:00:00 EET | Business Wire | Press release
TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings the latest HPC, cloud and storage platforms powered by AMD EPYC™ 9004 Series processors for the next generation server architecture and energy efficiency at SC22, Booth #2000 in the Kay Bailey Hutchison Convention Center Dallas through November 17th.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005027/en/
TYAN Server Platforms Powered by AMD EPYC 9004 Series Processors are Designed for the Next Generation Server Architecture (Photo: Business Wire)
“Facing the post-COVID economy world, data centers are required to build on more environmentally friendly, secure and flexible features to respond to the growing of teleworking, video streaming, IoT and 5G,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation’s Server Infrastructure BU. “TYAN’s new server platforms, powered by 4th Gen AMD EPYC processors, efficiently enable data centers by doing more tasks with the same number of servers.”
"4th Gen AMD EPYC processors are the world's highest performance server CPUs that deliver leadership energy efficiency as well as low total cost of ownership across workloads and industries. By adopting 4th Gen AMD EPYC processors, enterprises can optimize their data center footprint to do more with less, accelerating their core business while helping address their sustainability goals," said Ram Peddibhotla, corporate vice president, EPYC product management, AMD.
Optimized for the most demanding workloads in today’s HPC data centers
Leveraging 4th Gen AMD EPYC processors’ support for high performance DDR5 memory and fast PCIe® Gen 5 I/O, TYAN’s HPC platforms enable the high performance demands of today’s AI and machine learning applications. The Tomcat HX S8050 server motherboard provides eight DDR5 DIMM slots, five PCIe 5.0 x16 slots, four MCIO connectors, two NVMe M.2 slots, two 10GbE and two GbE onboard Ethernet ports in CEB (12" x 10.5") form factor.
The Transport HX FT65T-B8050 is a rack-convertible pedestal server platform featuring a single AMD EYPC 9004 Series processor, eight DDR5 DIMM slots, eight 3.5” SATA and two 2.5” NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8050 supports up to two double-wide PCIe 5.0 x16 professional GPUs along with two additional high-speed networking adapters for parallel clustered workloads.
Data cache and high-density with front I/O servers to power the cloud
TYAN’s cloud platforms benefit from the innovations of AMD EPYC 9004 Series processors and are designed for cloud and data analytics applications that help move data faster. The Transport CX GC68A-B8056 is a cost-optimized single-socket server platform featuring 24 DDR5 DIMM slots, a pair of PCIe 5.0 x16 expansion slots, one OCP 3.0 LAN mezzanine slot and two 10GbE onboard Ethernet ports in 1U configuration. The GC68A-B8056 accommodates twelve 2.5” tool-less drive bays supporting NVMe U.2 devices for applications which require outstanding compute cores as well as high performance storage I/Os.
The Transport CX TD76-B8058 is a 2U multi-node server platform with four front-service nodes. Each node supports one AMD EPYC 9004 Series processor, 16 DDR5 DIMM slots, four hot-swap E1.S drive bays, two internal NVMe M.2 slots, one standard PCIe 5.0 x16 expansion, and one OCP 3.0 LAN mezzanine slot. The platform is suited for high-density data center deployment, front-end web servers, and variety of scale-out applications with large numbers of nodes.
Hybrid and all-flash storage server to maximize application performance
TYAN’s storage platforms are designed to deliver massive data I/O between memory and storage devices for cloud applications. TYAN's Transport SX TS70-B8056 and Transport SX TS70A-B8056 are 2U single-socket storage servers with support for 24 DDR5 DIMM slots, three PCIe 5.0 and one OCP 3.0 LAN mezzanine slots. The TS70-B8056 accommodates twelve front 3.5” drive bays with up to four NVMe U.2 support, and two rear 2.5” NVMe U.2 hot-swap, tool-less drive bays for boot drive deployment; the TS70A-B8056 offers 26 2.5” NVMe U.2 hot-swap, tool-less drive bays for high IOPs requirement in high-performance data streaming applications.
Supporting Resources:
Please watch this video about TYAN 4th Gen AMD EPYC processor-based servers designed for modern data centers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005027/en/
Contact information
MiTAC Computing Technology Corporation/ Server Infrastructure Business Unit
Fenny Chen
fenny.chen@tyan.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom